QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:FULC

Fulcrum Therapeutics (FULC) Stock Forecast, Price & News

$3.15
0.00 (0.00%)
(As of 06/7/2023 ET)
Compare
Today's Range
$3.11
$3.35
50-Day Range
$2.26
$3.80
52-Week Range
$2.25
$15.00
Volume
731,159 shs
Average Volume
1.12 million shs
Market Capitalization
$194.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Fulcrum Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
217.5% Upside
$10.00 Price Target
Short Interest
Healthy
6.38% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Fulcrum Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$695 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.82) to ($1.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

271st out of 981 stocks

Pharmaceutical Preparations Industry

115th out of 464 stocks


FULC stock logo

About Fulcrum Therapeutics (NASDAQ:FULC) Stock

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Receive FULC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FULC Stock News Headlines

Fulcrum Therapeutics (FULC) Receives a Hold from Stifel Nicolaus
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Fulcrum Therapeutics (FULC) Gets a Hold from Stifel Nicolaus
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
H.C. Wainwright Remains a Hold on Fulcrum Therapeutics (FULC)
Q1 2023 Fulcrum Therapeutics Inc Earnings Call
Fulcrum Therapeutics appoints new executive chief
What Wall Street expects from Fulcrum Therapeutics's earnings
See More Headlines

FULC Price History

FULC Company Calendar

Last Earnings
3/09/2023
Today
6/07/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FULC
Fax
N/A
Employees
104
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+217.5%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
8 Analysts

Profitability

Net Income
$-109,870,000.00
Net Margins
-2,687.81%
Pretax Margin
-2,687.81%

Debt

Sales & Book Value

Annual Sales
$6.34 million
Book Value
$3.82 per share

Miscellaneous

Free Float
60,215,000
Market Cap
$194.54 million
Optionable
Not Optionable
Beta
2.11

Key Executives

  • Robert J. GouldRobert J. Gould
    President, Chief Executive Officer & Director
  • Mel Hayes
    Chief Operating Officer
  • Mani Sundararajan
    Senior Vice President-Technical Operations
  • Jeffrey W. Jacobs
    Chief Scientific Officer
  • Iain Fraser
    Chief Medical Officer













FULC Stock - Frequently Asked Questions

Should I buy or sell Fulcrum Therapeutics stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FULC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FULC, but not buy additional shares or sell existing shares.
View FULC analyst ratings
or view top-rated stocks.

What is Fulcrum Therapeutics' stock price forecast for 2023?

8 equities research analysts have issued 12-month price objectives for Fulcrum Therapeutics' stock. Their FULC share price forecasts range from $3.00 to $21.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 217.5% from the stock's current price.
View analysts price targets for FULC
or view top-rated stocks among Wall Street analysts.

How have FULC shares performed in 2023?

Fulcrum Therapeutics' stock was trading at $7.28 at the beginning of 2023. Since then, FULC stock has decreased by 56.7% and is now trading at $3.15.
View the best growth stocks for 2023 here
.

Are investors shorting Fulcrum Therapeutics?

Fulcrum Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 3,940,000 shares, a decline of 17.6% from the April 30th total of 4,780,000 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is currently 3.2 days.
View Fulcrum Therapeutics' Short Interest
.

When is Fulcrum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our FULC earnings forecast
.

How were Fulcrum Therapeutics' earnings last quarter?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its earnings results on Thursday, March, 9th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.01. The company earned $0.69 million during the quarter, compared to analysts' expectations of $1.92 million. Fulcrum Therapeutics had a negative net margin of 2,687.81% and a negative trailing twelve-month return on equity of 49.35%.

What ETFs hold Fulcrum Therapeutics' stock?

ETFs with the largest weight of Fulcrum Therapeutics (NASDAQ:FULC) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).ALPS Medical Breakthroughs ETF (SBIO).

What other stocks do shareholders of Fulcrum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO).

When did Fulcrum Therapeutics IPO?

(FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

What is Fulcrum Therapeutics' stock symbol?

Fulcrum Therapeutics trades on the NASDAQ under the ticker symbol "FULC."

Who are Fulcrum Therapeutics' major shareholders?

Fulcrum Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (9.97%), RTW Investments LP (8.92%), Suvretta Capital Management LLC (8.38%), BlackRock Inc. (6.77%), Cowen AND Company LLC (3.52%) and Geode Capital Management LLC (1.72%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Diego Cadavid, Greg Tourangeau, James A Geraghty, Owen B Wallace, Peter G Thomson, Peter G Thomson, Ra Capital Management, LP, Robert J Gould and Robert J Gould.
View institutional ownership trends
.

How do I buy shares of Fulcrum Therapeutics?

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fulcrum Therapeutics' stock price today?

One share of FULC stock can currently be purchased for approximately $3.15.

How much money does Fulcrum Therapeutics make?

Fulcrum Therapeutics (NASDAQ:FULC) has a market capitalization of $194.54 million and generates $6.34 million in revenue each year. The company earns $-109,870,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.

How many employees does Fulcrum Therapeutics have?

The company employs 104 workers across the globe.

How can I contact Fulcrum Therapeutics?

Fulcrum Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.fulcrumtx.com. The company can be reached via phone at (617) 651-8851 or via email at christina.tartaglia@sternir.com.

This page (NASDAQ:FULC) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -